- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04073550
Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer
August 27, 2019 updated by: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Randomized, Double-Blind, Multicenter, Phase Ⅲ Study of Anlotinib Hydrochloride Capsule Combined With Topotecan Versus Placebo Combined With Topotecan in Subjects With Small Cell Lung Cancer
Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in cell proliferation such as PDGFRα/β, c-Kit, and Ret have significant inhibitory activities.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
184
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yuankai Shi, Master
- Phone Number: 010-87788293
- Email: syuankaipumc@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100083
- Beijing Cancer Hospital
-
Contact:
- Ziping Wang, Doctor
- Phone Number: 010-88196456
- Email: wangzp2007@126.com
-
Beijing, Beijing, China, 100083
- Cancer Hospital Chinese Academy of Medical Sciences
-
Contact:
- Yuankai Shi, Master
- Phone Number: 010-87788293
- Email: syuankaipumc@126.com
-
Principal Investigator:
- Yuankai Shi, Master
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Small cell lung cancer patients.
- The clinical stage at baseline is extensive.
- A measurable lesion.
- Disease progression.
- ≥ 18 years old; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Life expectancy ≥ 3 months.
- Adequate laboratory indicators.
- No pregnant or breastfeeding women, and a negative pregnancy test.
- Understood and signed an informed consent form.
Exclusion Criteria:
- Has used topotecan and anlotinib hydrochloride capsules.
- Has used other anti-angiogenic drugs and immunologically targeted drugs.
- Has other malignant tumors within 5 years.
- Symptomatic brain metastasis.
- Has a variety of factors affecting oral medications.
- Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage.
- Spinal cord compression.
- Has received radiotherapy, chemotherapy, surgery less than 4 weeks before randomization.
- Adverse events caused by previous treatment did not recover to grade 1.
- Has received major surgical treatment within 4 weeks before randomization.
- Arteriovenous thrombosis occurred within 6 months.
- Has drug abuse history that unable to abstain from or mental disorders.
- Has severe or uncontrolled disease.
- Participated in other clinical trials within 4 weeks.
- Tumor invades the large blood vessels.
- Daily hemoptysis ≥2.5 mL within 1 month before the first dose.
- According to the investigators' judgement.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Experimental group
Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
|
A multi-target receptor tyrosine kinase inhibitor.
A topoisomerase I inhibitor.
|
PLACEBO_COMPARATOR: Placebo group
Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
|
A topoisomerase I inhibitor.
Anlotinib blank analog capsule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS) evaluated by IRC
Time Frame: up to 24 months
|
PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause; IRC defined as Independent Review Committee.
|
up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS) evaluated by investigator
Time Frame: up to 24 months
|
PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.
|
up to 24 months
|
Overall survival (OS)
Time Frame: up to 24 months
|
OS defined as the time from randomization to death from any cause.
Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.
|
up to 24 months
|
Overall Response Rate (ORR)
Time Frame: up to 24 months
|
Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR).
|
up to 24 months
|
Disease Control Rate (DCR)
Time Frame: up to 24 months
|
Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).
|
up to 24 months
|
Duration of Overall Response (DOR)
Time Frame: up to 24 months
|
The time when the patient first achieved complete or partial remission to disease progression.
|
up to 24 months
|
PFS rate at month 6
Time Frame: up to 6 months
|
The percentage of PFS at month 6.
|
up to 6 months
|
OS rate at month 6
Time Frame: up to 6 months
|
The percentage of OS at month 6.
|
up to 6 months
|
OS rate at month 12
Time Frame: up to 12 months
|
The percentage of OS at month 12.
|
up to 12 months
|
The efficacy of intracranial lesions
Time Frame: up to 24 months
|
To evaluate the efficacy of of intracranial lesions.
|
up to 24 months
|
Adverse Event (AE)
Time Frame: up to 24 months
|
Safety data
|
up to 24 months
|
Serious Adverse Event (SAE)
Time Frame: up to 24 months
|
Safety data
|
up to 24 months
|
Abnormal laboratory test index
Time Frame: up to 24 months
|
Safety data
|
up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
October 31, 2019
Primary Completion (ANTICIPATED)
July 31, 2021
Study Completion (ANTICIPATED)
July 31, 2022
Study Registration Dates
First Submitted
August 27, 2019
First Submitted That Met QC Criteria
August 27, 2019
First Posted (ACTUAL)
August 29, 2019
Study Record Updates
Last Update Posted (ACTUAL)
August 29, 2019
Last Update Submitted That Met QC Criteria
August 27, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Topotecan
Other Study ID Numbers
- ALTN-12-III-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Cancer
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
Washington University School of MedicineMerck Sharp & Dohme LLCWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Small Cell Lung Extensive Stage
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedTobacco Use Disorder | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Peking Union Medical College HospitalRecruitingNon Small Cell Lung Cancer Stage III | Small-Cell Lung CancerChina
-
University of Maryland, BaltimoreUniversity of Maryland, College ParkTerminatedNon-Small Cell Lung Cancer, Small Cell Lung Cancer | Platinum Responsive MalignanciesUnited States
Clinical Trials on Anlotinib
-
First People's Hospital of HangzhouChia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent High-grade GliomaChina
-
Peng YuanCompletedBreast Neoplasm | Antineoplastic Agents | AnlotinibChina
-
Peking Union Medical College HospitalRecruitingPheochromocytoma | ParagangliomaChina
-
Peking Union Medical College HospitalRecruitingParaganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, MalignantChina
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Non-small Cell Lung Cancer | Lung NeoplasmChina
-
Sun Yat-sen UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Small Cell Lung Cancer | Lung NeoplasmChina
-
Hunan Cancer HospitalFuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...RecruitingSmall Cell Lung CancerChina
-
Peking Union Medical College HospitalRecruiting
-
Sun Yat-sen UniversityRecruitingSarcoma,Soft TissueChina